Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Helixate

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Anti-drug antibodies to coagulation factor VIII (fVIII), often termed inhibitors, present the greatest economical and treatment… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2018
2018
Essentials Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in… Expand
2018
2018
Hemophilia A is a X-linked recessive bleeding disorder consecutive to the lack of circulating pro-coagulant factor VIII (FVIII… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
2014
2014
The administration of therapeutic factor VIII (FVIII) to treat or prevent haemorrhages in haemophilia A patients results, in up… Expand
2014
2014
taken as reference in RODIN gave, in the frame of a recent prospective study (EPIC), a relatively high incidence of inhibitors… Expand
Review
2001
Review
2001
  • B. Boedeker
  • Seminars in thrombosis and hemostasis
  • 2001
  • Corpus ID: 34046392
The state-of-the-art treatment for hemophilia A is replacement therapy with recombinant factor VIII (rFVIII) made possible by… Expand
1998
1998
Recombinant hirudin (rH) is a highly specific thrombin inhibitor which is under clinical investigation for various thrombotic… Expand